Evaluation of proprotein convertase subtilsin /kexin 9(PCSK9) in serum of men hypertensive patients

Автор: Al-mohtaser Y.A.H.M., Al-dujaili A.N.G.

Статья в выпуске: 31, 2024 года.

Бесплатный доступ

High blood pressure is considered a major factor for the development of heart disease and vascular disease in elderly people, due to higher tension in arteries leading to hypertension. PCSK9 is a proprotein convertase that increases circulating LDL levels by directing hepatic LDL receptors into lysosomes for degradation. The effects of PCSK9 on hepatic LDL receptors and contribution to atherosclerosis via the induction of hyperlipidemia are well defined.

Proprotein convertase subtilsin /kexin 9(pcsk9), cholesterol (cho), triglyceride (tg), high density lipoprotein (hdl), & low-density lipoprotein (ldl)

Короткий адрес: https://sciup.org/148328847

IDR: 148328847 | DOI: 10.18137/cardiometry.2024.31.174184

Список литературы Evaluation of proprotein convertase subtilsin /kexin 9(PCSK9) in serum of men hypertensive patients

Beltrami M, et al. Long-Term Prevalence of Systolic Dysfunction in MYBPC3 Versus MYH7-Related Hypertrophic Cardiomyopathy. Circulation: Genomic and Precision Medicine. 2023;16(4):363-71.
Kuzmich N, et al. PCSK9 as a Target for Development of a New Generation of Hypolipidemic Drugs. Molecules. 2022;27(2):434.
Ahamad S, Bhat SA. Recent update on the development of PCSK9 inhibitors for hypercholesterolemia treatment. Journal of Medicinal Chemistry. 2022;65(23):15513-39.
Seidah NG, Garçon D. Expanding biology of PCSK9: roles in atherosclerosis and beyond. Current atherosclerosis reports. 2022;24(10):821-30.
Laurent S, Boutouyrie P. Arterial stiffness and hypertension in the elderly. Frontiers in cardiovascular medicine. 2020;7:544302.
Silla A, et al. Treatment with PCSK9 inhibitor evolocumab improves vascular oxidative stress and arterial stiffness in hypercholesterolemic patients with high cardiovascular risk. Antioxidants. 2023;12(3):578.
Lupo MG, et al. PCSK9 promotes arterial medial calcification. Atherosclerosis. 2022;346:86-97.
Schremmer J, et al. Chronic PCSK9 inhibitor therapy leads to sustained improvements in endothelial function, arterial stiffness, and microvascular function. Microvascular research. 2023;148:104513.
Hwang HS, et al. Circulating PCSK9 level and risk of cardiovascular events and death in hemodialysis patients. Journal of Clinical Medicine. 2020;9(1): 244.
Parthymos I, et al. Lipoprotein (a) as a treatment target for cardiovascular disease prevention and related therapeutic strategies: a critical overview. European Journal of Preventive Cardiology. 2022;29(5):739-55.
Wang D, Zhang D. Safety issues associated with the clinical application of Pcsk9 inhibitors: Current findings. Cardiology in Review. 2023;31(3):155-61.
Merćep I, et al. Present and future of dyslipidaemia treatment—a review. Journal of Clinical Medicine. 2023;12(18):5839.
Alsayed N, et al. Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East: 2021 update. Atherosclerosis. 2022;343:28-50.
Afosah DK, RA Al-Horani, Sulfated non-saccharide glycosaminoglycan mimetics as novel drug discovery platform for various pathologies. Current medicinal chemistry. 2020;27(21):3412-47.
Incalza MA, et al. Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. Vascular pharmacology, 2018. 100: p. 1-19.
Roy PK, et al. Prospects of potential adipokines as therapeutic agents in obesity-linked atherogenic dyslipidemia and insulin resistance. The Egyptian Heart Journal. 2023;75(1):1-28.
Milojević A, et al. Effects of Apnea, Obesity, and Statin Therapy on Proprotein Convertase Subtilisin/ Kexin 9 Levels in Patients with Obstructive Sleep Apnea. Medical Principles and Practice. 2022;31(3):293-300.
Szudzik M, et al. High-fat diet causes hepatic steatosis, increased plasma low-density lipoprotein levels, and alters the PCSK9-lDLR system more pronouncedly than a high-carbohydrates diet in rats. Atherosclerosis. 2023;379:S101.
Domingo E, et al. Targeting systemic inflammation in metabolic disorders. A therapeutic candidate for the prevention of cardiovascular diseases? Pharmacological Research. 2024. p. 107058.
Kiyosue A, et al. Safety and Effectiveness of Alirocumab, a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor, in Patients With Familial or Non-Familial Hypercholesterolemia. A Post-Marketing Survey (J-POSSIBLE). Circulation Journal. 2023; 87(6):834-46.
Rogula S, et al. Inclisiran—Silencing the Cholesterol, Speaking up the Prognosis. Journal of Clinical Medicine. 2021;10(11):2467.
Lebeau PF, et al. The emerging roles of intracellular PCSK9 and their implications in endoplasmic reticulum stress and metabolic diseases. Metabolites. 2022;12(3):215.
Abdelwahed KS. Pseurotin a as a Novel PCSK9 Axis Lead Modulator for the Control of Breast and Prostate Malignancy Recurrences. 2021, University of Louisiana at Monroe.
Yang SH, et al. Plasma PCSK9 level is unrelated to blood pressure and not associated independently with carotid intima–media thickness in hypertensives. Hypertension Research, 2016;39(8):598-605.
Fairoozy RH. Genetic functional studies of low density lipoprotein-cholesterol (LDL-C) associated variants and the genetic spectrum of familial hypercholesterolemia in different ethnic groups. 2018, UCL (University College London).
Schlüter KD, et al. Coming back to physiology: extra hepatic functions of proprotein convertase subtilisin/ kexin type 9. Frontiers in Physiology. 2020; 11:598649.
Li A, et al. Efficacy of oats for dyslipidemia: a systematic review and meta-analysis. Food & Function, 2024.
Bhatnagar A. Environmental cardiology: studying mechanistic links between pollution and heart disease. Circulation research. 2006;99(7): p. 692-705.
Laufs U, et al. Clinical review on triglycerides. European heart journal. 2020;41(1):99-109.
Sawaguchi J, et al., The circulating furin-cleaved/mature PCSK9 ratio has a potential prognostic significance in statin-naïve patients with acute ST elevation myocardial infarction. Atherosclerosis Plus. 2022; 50:50-6.
Schulz R, et al. Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9). Basic research in cardiology. 2015;110:1-19.
Wichaiyo SP, et al. Functional Roles of Furin in Cardio-Cerebrovascular Diseases. ACS Pharmacology & Translational Science. 2023.
Puri R, et al. Proposed low-density lipoprotein cholesterol goals for secondary prevention and familial hypercholesterolemia in India with focus on PCSK9 inhibitor monoclonal antibodies: Expert consensus statement from Lipid Association of India. Journal of clinical lipidology. 2020;14(2):e1-e13.
Nussbaumerova B, H Rosolova. Obesity and Dyslipidemia. Current Atherosclerosis Reports. 2023; 25(12):947-55.

Еще

Статья научная